Key Takeaways
- Pfizer wins $10 billion acquisition of Metsera after beating Novo Nordisk
- Metsera board unanimously approved Pfizer’s improved $86.25 per share offer
- FTC concerns over antitrust risks influenced decision against Novo Nordisk deal
- Shareholder vote scheduled for November 13 to finalize the merger
Pfizer has secured a major victory in the pharmaceutical sector, finalizing a $10 billion deal to acquire biotechnology firm Metsera after a intense bidding war with Danish rival Novo Nordisk.
The US drugmaker’s improved offer of $86.25 per share received unanimous board approval from Metsera, which specializes in obesity treatments. Shareholders will vote on the merger on November 13, with closure expected immediately afterward.
Bidding War and Valuation Surge
Pfizer’s final proposal nearly doubles Metsera’s valuation compared to their initial September agreement. This triggered a fierce price competition between the two pharmaceutical giants before Novo Nordisk withdrew from the race.
Novo Nordisk, maker of popular weight-loss drug Wegovy and diabetes treatment Ozempic, confirmed it would not increase its offer further. The company stated it would continue pursuing “strategic acquisitions” aligned with its long-term growth objectives.
Regulatory Concerns Shape Outcome
Metsera revealed that the US Federal Trade Commission had raised concerns about “potential risks” associated with the proposed Novo Nordisk transaction under antitrust laws. This significantly influenced the board’s decision to support Pfizer’s offer instead.
The board concluded the Novo Nordisk deal “presents unacceptably high legal and regulatory risks… compared to the proposed merger with Pfizer.” Novo Nordisk maintained that its proposal was “compliant with antitrust laws.”
Global Obesity Treatment Market Heats Up
The battle for Metsera highlights intensifying competition in the global obesity treatment market, where pharmaceutical companies are racing to capture market share amid surging demand for weight-loss and diabetes medications.
According to World Health Organization data, more than one billion people worldwide were living with obesity and over 800 million with diabetes as of 2022, creating substantial market opportunities for effective treatments.
